Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNRX-5133 in healthy volunteers
NCT02955459Phase 1Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in bacterial infection comparing VNRX-5133 with Placebo (2 arms). Primary endpoint: Number of subjects with adverse events at 17 days. Started Nov 2016; status: completed.
02
Drugs
taniborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02955459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955459.